• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15914 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2017 Agency for Healthcare Research and Quality (AHRQ) Management of suspected opioid overdose with naloxone by emergency medical services personnel
2017 Agency for Healthcare Research and Quality (AHRQ) Management of uterine fibroids
2017 Agency for Healthcare Research and Quality (AHRQ) Methods for evaluating natural experiments in obesity: a systematic evidence review
2017 Agency for Healthcare Research and Quality (AHRQ) The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management
2017 Agency for Healthcare Research and Quality (AHRQ) Treatment for adults with schizophrenia
2017 Agency for Healthcare Research and Quality (AHRQ) Treatments for basal cell and squamous cell carcinoma of the skin
2017 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Home use of a mechanical cough-assist insufflation-exsufflation device for adults with neuromuscular diseases who do not require ventilatory support]
2017 Canary Health Service [Early detection of hepatocarcinoma in patients at risk]
2017 The Regional Health Technology Assessment Centre (HTA-centrum) Term breech presentation - caesarean section versus vaginal delivery
2017 The Regional Health Technology Assessment Centre (HTA-centrum) New versus old types of pessaries and gels as contraceptives for women
2017 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of intraocularly administered vascular endothelial growth factor inhibitors for macular disease
2017 The Regional Health Technology Assessment Centre (HTA-centrum) Rectal cancer with complete clinical remission after chemoradiotherapy: resection or watch-and-wait?
2017 The Regional Health Technology Assessment Centre (HTA-centrum) Repetitive transcranial magnetic stimulation in the management of chronic neuropathic pain
2017 The Regional Health Technology Assessment Centre (HTA-centrum) Acellular dermal matrix support for breast reconstruction after mastectomy
2017 National Institute for Health and Care Excellence (NICE) Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib. NICE technology appraisal guidance 427
2017 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 428
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. NICE technology appraisal guidance 429
2017 National Institute for Health and Care Excellence (NICE) Sofosbuvir-velpatasvir for treating chronic hepatitis C. NICE technology appraisal guidance 430
2017 National Institute for Health and Care Excellence (NICE) Everolimus for advanced renal cell carcinoma after previous treatment. NICE technology appraisal guidance 432
2017 National Institute for Health and Care Excellence (NICE) Apremilast for treating active psoriatic arthritis. NICE technology appraisal guidance 433
2017 National Institute for Health and Care Excellence (NICE) Elotuzumab for previously treated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 434
2017 National Institute for Health and Care Excellence (NICE) Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal). NICE technology appraisal guidance 435
2017 National Institute for Health and Care Excellence (NICE) Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 436
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal). NICE technology appraisal guidance 437
2017 National Institute for Health and Care Excellence (NICE) Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 438
2017 National Institute for Health and Care Excellence (NICE) Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. NICE technology appraisal guidance 439
2017 National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2017 National Institute for Health and Care Excellence (NICE) Ixekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 442
2017 National Institute for Health and Care Excellence (NICE) Obeticholic acid for treating primary biliary cholangitis. NICE technology appraisal guidance 443
2017 National Institute for Health and Care Excellence (NICE) Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017 National Institute for Health and Care Excellence (NICE) Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 445
2017 National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. NICE technology appraisal guidance 450
2017 National Institute for Health and Care Excellence (NICE) Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal). NICE technology appraisal guidance 452
2017 National Institute for Health and Care Excellence (NICE) Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2017 National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NICE technology appraisal guidance 455
2017 National Institute for Health and Care Excellence (NICE) Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2017 National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2017 National Institute for Health and Care Excellence (NICE) Adalimumab and dexamethasone for treating non-infectious uveitis. NICE technology appraisal guidance 460
2017 National Institute for Health and Care Excellence (NICE) Roflumilast for treating chronic obstructive pulmonary disease. NICE technology appraisal guidance 461
2017 National Institute for Health and Care Excellence (NICE) Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 462
2017 National Institute for Health and Care Excellence (NICE) Bisphosphonates for treating osteoporosis. NICE technology appraisal guidance 464
2017 National Institute for Health and Care Excellence (NICE) Baricitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 466
2017 National Institute for Health and Care Excellence (NICE) Holoclar for treating limbal stem cell deficiency after eye burns. NICE technology appraisal guidance 467
2017 National Institute for Health and Care Excellence (NICE) Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal). NICE technology appraisal guidance 468
2017 National Institute for Health and Care Excellence (NICE) Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 469
2017 National Institute for Health and Care Excellence (NICE) Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
2017 National Institute for Health and Care Excellence (NICE) Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2017 National Institute for Health and Care Excellence (NICE) Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 475
2017 National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer. NICE technology appraisal guidance 476
2017 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 478
2017 National Institute for Health and Care Excellence (NICE) Reslizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 479
2017 National Institute for Health and Care Excellence (NICE) Tofacitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 480
2017 National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in adults. NICE technology appraisal guidance 481
2017 National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in children and young people. NICE technology appraisal guidance 482
2017 National Institute for Health and Care Excellence (NICE) Sarilumab for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 485
2017 National Institute for Health and Care Excellence (NICE) Aflibercept for treating choroidal neovascularisation. NICE technology appraisal guidance 486
2017 National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours. NICE technology appraisal guidance 488
2017 National Institute for Health and Care Excellence (NICE) Vismodegib for treating basal cell carcinoma. NICE technology appraisal guidance 489
2017 National Institute for Health and Care Excellence (NICE) Naltrexone–bupropion for managing overweight and obesity. NICE technology appraisal guidance 494
2017 National Institute for Health and Care Excellence (NICE) Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 496
2017 National Institute for Health and Care Excellence (NICE) Endobronchial valve insertion to reduce lung volume in emphysema. NICE interventional procedures guidance 600
2017 National Institute for Health and Care Excellence (NICE) Transcutaneous microwave ablation for severe primary axillary hyperhidrosis. NICE interventional procedures guidance 601
2017 National Institute for Health and Care Excellence (NICE) Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. NICE interventional procedures guidance 602
2017 National Institute for Health and Care Excellence (NICE) Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. NICE interventional procedures guidance 603
2017 National Institute for Health and Care Excellence (NICE) Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2017 National Institute for Health and Care Excellence (NICE) Processed nerve allografts to repair peripheral nerve discontinuities. NICE interventional procedures guidance 597
2017 National Institute for Health and Care Excellence (NICE) Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea. NICE interventional procedures guidance 598
2017 National Institute for Health and Care Excellence (NICE) Total distal radioulnar joint replacement for symptomatic joint instability or arthritis. NICE interventional procedures guidance 595
2017 National Institute for Health and Care Excellence (NICE) Extracranial to intracranial bypass for intracranial atherosclerosis. NICE interventional procedures guidance 596
2017 National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease. NICE interventional procedures guidance 593
2017 National Institute for Health and Care Excellence (NICE) Ab externo canaloplasty for primary open-angle glaucoma. NICE interventional procedures guidance 591
2017 National Institute for Health and Care Excellence (NICE) High-intensity focused ultrasound for symptomatic breast fibroadenoma. NICE interventional procedures guidance 592
2017 National Institute for Health and Care Excellence (NICE) Radiofrequency treatment for haemorrhoids. NICE interventional procedures guidance 589
2017 National Institute for Health and Care Excellence (NICE) Transcatheter aortic valve implantation for aortic stenosis. NICE interventional procedures guidance 586
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 581
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair uterine prolapse. NICE interventional procedures guidance 582
2017 National Institute for Health and Care Excellence (NICE) Sacrocolpopexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 583
2017 National Institute for Health and Care Excellence (NICE) Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse. NICE interventional procedures guidance 584
2017 National Institute for Health and Care Excellence (NICE) Endoscopic full thickness removal of non-lifting colonic polyps. NICE interventional procedures guidance 580
2017 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating pancreatic cancer. NICE interventional procedures guidance 579
2017 National Institute for Health and Care Excellence (NICE) Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain. NICE interventional procedures guidance 578
2017 National Institute for Health and Care Excellence (NICE) Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women. NICE interventional procedures guidance 576
2017 National Institute for Health and Care Excellence (NICE) Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. NICE interventional procedures guidance 577
2017 National Institute for Health and Care Excellence (NICE) Lateral interbody fusion in the lumbar spine for low back pain. NICE interventional procedures guidance 574
2017 National Institute for Health and Care Excellence (NICE) Trabecular stent bypass microsurgery for open-angle glaucoma. NICE interventional procedures guidance 575
2017 National Institute for Health and Care Excellence (NICE) SecurAcath for securing percutaneous catheters. NICE medical technologies guidance 34
2017 National Institute for Health and Care Excellence (NICE) ENDURALIFE powered CRT-D devices for treating heart failure. NICE medical technologies guidance 33
2017 National Institute for Health and Care Excellence (NICE) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography. NICE medical technologies guidance 32
2017 National Institute for Health and Care Excellence (NICE) HumiGard for preventing inadvertent perioperative hypothermia. NICE medical technologies guidance 31
2017 National Institute for Health and Care Excellence (NICE) Tests in secondary care to identify people at high risk of ovarian cancer. NICE diagnostics guidance 31
2017 National Institute for Health and Care Excellence (NICE) Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis. NICE diagnostics guidance 29
2017 National Institute for Health and Care Excellence (NICE) Virtual chromoendoscopy to assess colorectal polyps during colonoscopy. NICE diagnostics guidance 28
2017 National Institute for Health and Care Excellence (NICE) Molecular testing strategies for Lynch syndrome in people with colorectal cancer. NICE diagnostics guidance 27
2017 Canary Health Service [Tools for early detection of disease-related malnutrition for adult population in the hospital setting]
2017 Canary Health Service [Safety, clinical effectiveness and cost-effectiveness of platelet-rich plasma for the treatment of chronic wounds]
2017 Canary Health Service [Cost-effectiveness of pneumococcal vaccination in adults older than 60 years]
2017 Canary Health Service [Argus II. Retinal Prosthesis System]
2017 Canary Health Service [High definition direct current transcranial stimulation (HD-tDCS) in Fibromyalgia]